Share this article
Share this article
SHANGHAI, Dec. 22, 2020 /PRNewswire/ 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading digital healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced the successful completion of new capital injection in its principal PRC subsidiary by a selected group of strategic and mission-driven investors.
On December 22, 2020, 1 Pharmacy Yaofang Technology (Shanghai) Co., Ltd. (previously known as Yao Fang Information Technology (Shanghai) Co., Ltd.) ( Yao Fang Shanghai ), the principal operating subsidiary of 111 in China, completed a new round of capital injection from strategic investors. According to the investment agreements, the investors invested in Yao Fang Shanghai an aggregate of RMB515 million (approximately US$78.75 million
国药监发布不合格化妆品通告 希恩等祛痘类产品成违禁添加重灾区_中国网 china.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from china.com.cn Daily Mail and Mail on Sunday newspapers.
109批次化妆品被国药监点名,染发品类成重灾区 sina.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.cn Daily Mail and Mail on Sunday newspapers.